Botanical Integrity: The UK’s 2026 Herbal Safety Standards
OXFORD – In April 2026, the United Kingdom is entering a new phase of botanical oversight, prioritizing molecular transparency and consumer safety over traditional anecdotal labeling. As the Food Standards Agency (FSA) and the MHRA tighten the intersection between nutrition and pharmacology, the focus has shifted to the rigorous enforcement of the Traditional Herbal Registration (THR) scheme.
The Ashwagandha and High-Potency Review
A major milestone this spring is the completion of the 2026 Safety Assessment on Adaptogens. Following a year-long review, UK health authorities have introduced mandatory labeling requirements for high-potency extracts like Ashwagandha and Rhodiola. Products must now clearly state standardized levels of active compounds—such as withanolides—while carrying specific warnings for those with thyroid conditions or those taking immunosuppressants. This move aims to professionalize the sector, ensuring that "herbal" does not equate to "unregulated."


